Raltegravir

ARV U.S. Brand Name

Isentress, Isentress HD

ARV Abbreviation(s)

RAL

U.S. FDA Label

Raltegravir Labeling (Package Insert)

ARV Class

Integrase inhibitors

First U.S. Approval

September 30, 2014

U.S. Manufacturer

Merck

Formulations

Strength	Formulation	Image	Description	Boosted
25 mg	Chewable Tablet Film-Coated Tablets	X	round yellow tablet with 473 imprint	No
100 mg	Chewable Tablet	X	orange oval tablet design and 477 imprint	No
100 mg	Oral Suspension	X	Isentress 100 mg singleuse packet for oral suspension	No
400 mg	Film-Coated Tablets	X	oval pick tablet pink tablet with 227 imprint	No
600 mg	Film-Coated Tablets	X	oval yellow tablet with design and 242 imprint	No

Generic Available?

Assistance Programs

Merck Helps

Displaying 1 - 53 of 53

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Rilpivirine (IM) Raltegravir	Green: Administer standard doses	Administer standard doses
Ritonavir RAL 1065	Green: Administer standard doses	Administer standard doses			400 mg x 1	Raltegravir AUC decreased 16%; Cmax decreased 24%
Tenofovir disoproxil fumarate RAL 735	Green: Administer standard doses	Administer standard doses		Cmax decrease 23%, AUC decrease 10%, Cmin decrease 13%	400 mg BID	Cmax increase 64%, AUC increase 49%
Etravirine RAL 532	Green: Administer standard doses	Administer standard doses		Etravirine Cmin increased 17%	400 mg BID	Raltegravir Cmin decreased 34%
Efavirenz RAL 412	Green: Administer standard doses	Administer standard doses			400 mg x 1	Raltegravir AUC decreased 36%; Cmin decreased 21%; Cmax decreased 36%
Raltegravir Valproic acid 325	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering, monitor for raltegravir efficacy
Raltegravir Oxcarbazepine 324	Orange: Minimal data to guide interaction	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Consider using alternative agents
Raltegravir Calcium carbonate 323	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 72%; Cmin decreased 48%	3000 mg single dose given with raltegravir	Not reported	Contraindicated. Use alternative agents.
Raltegravir Calcium carbonate 322	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 10%; Cmin decreased 57%	3000 mg single dose given 12 hours after raltegravir	Not reported	Contraindicated. Use alternative agents.
Raltegravir Aluminum and magnesium hydroxide antacid 321	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 49% if antacid given simultaneously. AUC decreased 51% if antacid given 2 hours before. AUC decreased 30% if antacid given 2 hours after. AUC decreased 19% if antacid given 4 hours before. AUC decreased 32% if antacid given 4 hours after. AUC decreased 11-13% if antacid given 6 hours before or 6 hours after.	20 mL single dose	Not reported	Contraindicated. Use alternative agents.
Raltegravir Aluminum and magnesium hydroxide antacid 320	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 14% if antacid given 12 horus after.	20 mL single dose	Not reported	Contraindicated. Use alternative agents.
Raltegravir Phenobarbital 319	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Raltegravir Eslicarbazepine 318	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Raltegravir CBZ 317	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Raltegravir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 316	Green: Administer standard doses	Administer standard doses		Raltegravir AUC increased 134%	paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg BID
Raltegravir DRV 315	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 29%; Cmin increased 38%; Cmax decreased 33%	600 mg Q12H with 100 mg ritonavir Q12H
Raltegravir RPV 314	Green: Administer standard doses	Administer standard doses		Raltegravir Cmin increased 27%	25 mg daily
Raltegravir SOF 313	Green: Administer standard doses	Administer standard doses		No significant change	400 mg x 1	Sofosbuvir Cmax decreased 43%; AUC decreased 27%
Raltegravir SOF/VEL 312	Green: Administer standard doses	Administer standard doses		Raltegravir Cmin increased 8%; AUC increased 5%.	400 mg / 100 mg	Not reported
Raltegravir G/P 311	Green: Administer standard doses	Administer standard doses		Raltegravir AUC increased 47%; Cmin increased 164%	300 / 120 mg daily	Not reported
Raltegravir ATV 310	Green: Administer standard doses	Administer standard doses		RAL AUC no significant change	300 mg BID	Not reported
Raltegravir ETR 309	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 10%; Cmin decreased 34%	200 mg BID	Not reported
Raltegravir RTV 308	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 16%; Cmax decreased 24%	100 mg BID	Not reported
Raltegravir Buprenorphine / naloxone 307	Green: Administer standard doses	Administer standard doses		No significant change	stable dose for at least 3 weeks	No significant change
Raltegravir EBR/GZR 306	Green: Administer standard doses	Administer standard doses		Increase RAL AUC 43% with grazoprevir	Elbasvir 50 mg daily with grazoprevir 100 mg daily	No significant change
Raltegravir LDV/SOF 305	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 15-27%	90 / 400 mg daily	No significant change
Raltegravir Pravastatin 304	Green: Administer standard doses	Administer standard doses		Raltegravir Cmax increased 31%; Cmin decreased 41%	40 mg daily	No significant change
Raltegravir Pravastatin 303	Green: Administer standard doses	Administer standard doses		Raltegravir AUC no significant change; Cmax increased 31%; Cmin decreased 41%	40 mg daily	No significant change
Raltegravir Midazolam 302	Green: Administer standard doses	Administer standard doses			2 mg x 1	No significant change
Raltegravir Lamotrigine 301	Green: Administer standard doses	Administer standard doses			100 mg	No significant change
Raltegravir MVC 300	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 37%; Cmin decreased 28%; Cmax decreased 33%	300 mg Q12H	Maraviroc Cmin decreased 21%; Cmax decreased 20%
Raltegravir ETR 299	Green: Administer standard doses	Administer standard doses		Not reported	200 mg	Etravirine AUC increased 10%, Cmin increased 17%
Raltegravir Ginkgo biloba 298	Green: Administer standard doses	Administer standard doses		No significant change	120 mg BID	Ginkgo biloba AUC increased 21%; Cmax increased 44%
Raltegravir Omeprazole 297	Green: Administer standard doses	Administer standard doses		Raltegravir AUC increased 39%; Cmax increased 50%; Cmin increased 24%	20 mg daily	Not reported
Raltegravir Omeprazole 296	Green: Administer standard doses	Administer standard doses		Raltegravir AUC increased 212%; Cmin increased 46%; Cmax increased 315%	20 mg daily x 4 days
Raltegravir Famotidine 295	Green: Administer standard doses	Administer standard doses		Raltegravir AUC increased 45%; Cmax increased 60%	20 mg daily given 2 hours before raltegravir
Raltegravir Calcium carbonate 294	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 55%; Cmin decreased 32%	3000 mg single dose	Not reported
Raltegravir ATV 293	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 72%; Cmax increased 53%; Cmin increased 95%	400 mg daily
Raltegravir ATV 292	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 41%; Cmax increased 24%; Cmin increased 77%	300 mg with 100 mg ritonavir daily
Raltegravir ATV 291	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 67%	400 mg daily	Not reported
Raltegravir TDF 290	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 49%; Cmax increased 64%	300 mg daily	Not reported
Raltegravir ATV 289	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 54%; Cmin increased 48%; Cmax increased 39%	300 mg BID on days 6-12 and days 13-26	Atazanavir AUC decreased 17%; Cmin decreased 29% (compared to atazanavir BID)
Raltegravir EFV 288	Green: Administer standard doses	Administer standard doses	Potential decrease in antiretroviral efficacy	Raltegravir AUC decreased 36%; Cmax 36%; Cmin decreased 21%	600 mg daily	Not reported
Raltegravir EFV 287	Green: Administer standard doses	Administer standard doses	Potential decrease in antiretroviral efficacy	Raltegravir AUC decreased 14%	600 mg daily	Not reported
Raltegravir RPT 286	Green: Administer standard doses	Adjust dosing to avoid reduced levels of raltegravir	Potential for increased raltegravir adverse effects if given with rifapentine once weekly; potential for loss of antiviral response if rifapentine coadministered daily	When given with rifapentine once weekly for 3 weeks raltegravir AUC increased 79%, Cmax increased 89% and Cmin decreased 12%. When given with rifapentine for 10 daily doses, Cmin decreased 41%	900 mg once weekly for 3 weeks or 600 mg once daily for 10 scheduled doses (days 1, 4?8 and 11?14)		When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine.
Raltegravir RFB 285	Yellow: Adjust dosing	Administer standard doses		Raltegravir AUC increased 19%; Cmax increased 39%; Cmin decreased 20%	300 mg daily x 14 d
Raltegravir RPT 284	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir		Raltegravir AUC increased 73%; Cmax increased 89%; Cmin decreased 44%	900 mg PO once weekly		When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine.
Raltegravir RIF 283	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir		Raltegravir AUC increased 27%; Cmin decreased 53%; Cmax increased 62% (compared to 400 mg raltegravir Q12H when given alone)	600 mg daily		Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.
Raltegravir RIF 282	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Potential decrease in antiretroviral efficacy	Raltegravir AUC increased 27%; Cmax increased 62%; Cmin decreased 53% (all compared to raltegravir 400 mg BID)	600 mg daily	Not reported	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.
Raltegravir RIF 281	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Potential decrease in antiretroviral efficacy	Raltegravir AUC decreased 40%; Cmax decreased 38%; Cmin decreased 61%	600 mg daily	Not reported	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.
Maraviroc RAL 57	Green: Administer standard doses	Administer standard doses		Maraviroc AUC decreased 14%; Cmax decreased 21%	400 mg BID	Raltegravir AUC decreased 37%; Cmin decreased 27%
Fostemsavir RAL + TDF 16	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 23%, AUC increased 7%, Cmin increased 17%	RAL 400 mg BID, TDF 300 mg once daily	Not reported
Raltegravir

Subscribe to Raltegravir